Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 183.35% | -3.76% | 101.34% | 92.22% | -4,411.36% |
| Total Depreciation and Amortization | 18.78% | -11.62% | -8.09% | -35.88% | -38.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.86% | 133.63% | -82.94% | -89.17% | 26.86% |
| Change in Net Operating Assets | -139.71% | -3,315.24% | 52.14% | 195.58% | 52.34% |
| Cash from Operations | -261.90% | -3,627.69% | 193.11% | 36.96% | 82.32% |
| Capital Expenditure | 1.23% | 49.33% | 50.42% | -55.18% | 56.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 104.74% | -- | -- | 125.83% | -- |
| Cash from Investing | -137.48% | -174.10% | 115.15% | 4.63% | 84.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.54% | -- | -19.53% | -- | -43.75% |
| Repurchase of Common Stock | -1,010.98% | -90.27% | 2.35% | 99.67% | 94.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -491.62% | -90.27% | 1.40% | 99.67% | 116.11% |
| Foreign Exchange rate Adjustments | -83.48% | -126.85% | 50.00% | -189.61% | 254.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,178.43% | -334.56% | 90.23% | 1,162.33% | 96.49% |